Emergent Biosolutions (EBS) Issues Q3 Miss
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Join SI Premium – FREE
Emergent Biosolutions (NYSE: EBS) reported Q3 EPS of $0.04, $0.06 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $58.8 million versus the consensus estimate of $63.59 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VNET Group (VNET) Misses Q2 EPS by 164c
- INVO Fertility (IVF) Tops Q2 EPS by 105c
- Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
